Scienture announces FDA Orange Book patent listing for Arbli

Scienture (SCNX) announces that the U.S. Food and Drug Administration has listed U.S. Patent Nos. 11890273 and 12156869, each with an expiration date of October 2041, in its Approved Drug Products with Therapeutic Equivalence Evaluations for Arbli, Oral Suspension, 10mg/mL, approved under New Drug Application. The ‘869 patent and the ‘273 patent, both titled, “Losartan Liquid Formulations and Methods of Use,” cover stable, liquid pharmaceutical compositions of Losartan and methods of treating patients in need of Losartan by administration of the novel formulations described. The listing reinforces Scienture’s intellectual property position and may serve as a basis for statutory exclusivity and market protection under the Hatch-Waxman Act.